Sanofi announces changes to its Executive Committee
Houman, Madeleine and Emmanuel will report to Sanofi’s CEO, Paul Hudson, and will be based in Paris, France. Brian, also reporting to Paul Hudson, will be based in Cambridge, US.
For the past 3 years, Sanofi has reshaped its discovery and development of therapeutics, built a robust pipeline and sharpened its research focus, employing cutting-edge therapeutic platforms and creating a culture that responds to the urgent needs of patients. As Sanofi’s new Head of Research & Development, Houman Ashrafian will be responsible for bolstering the company’s strategy to develop first or best-in-class medicines and growing the momentum of Sanofi’s pipeline in support of its emergence as a science-driven and innovation leader in the industry.
In this newly created role, Madeleine Roach will establish and lead the Business Operations Business Unit bringing together existing business service activities and driving further expansion of centralized services into a global unit with a focus on driving efficiency and productivity to fuel business growth and Sanofi’s investment in science. This new business unit will act as an enabler and operator of best-in-class business support capabilities across the company ensuring optimal cross-functional resource capacity and high-quality support across Sanofi´s full organization.
Emmanuel Frenehard, Chief Digital Officer, will lead Sanofi’s company-wide digital transformation and continue to push forward the company’s digital, data and technology strategy. Building on a solid foundation of digital tools and data, creating business value, developing the acquisition of new skills and promoting a digital and data driven culture, Emmanuel and his teams will notably support Sanofi’s goal to become the first biopharma company powered by artificial intelligence at scale, to accelerate innovation for patients and healthcare professionals.
Source link:https://www.sanofi.com/
